Compare · INMD vs STXS
INMD vs STXS
Side-by-side comparison of InMode Ltd. (INMD) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both INMD and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- INMD is the larger of the two at $788.9M, about 8.7x STXS ($90.2M).
- STXS has been more active in the news (7 items in the past 4 weeks vs 3 for INMD).
- INMD has more recent analyst coverage (20 ratings vs 6 for STXS).
- Company
- InMode Ltd.
- Stereotaxis Inc.
- Price
- -
- -
- Market cap
- $788.9M
- $90.2M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2019
- News (4w)
- 3
- 7
- Recent ratings
- 20
- 6
InMode Ltd.
InMode Ltd. designs, develops, manufactures, and markets minimally-invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company offers minimally-invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation. InMode Ltd. offers its products directly in United States, Canada, United Kingdom, Spain, India, Australia, and France, as well as through distributors in 47 countries. The company was formerly known as Invasix Ltd. and changed its name to InMode Ltd. in November 2017. InMode Ltd. was founded in 2008 and is headquartered in Yokneam, Israel.
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest INMD
- InMode Reports Third Quarter 2026 Financial Results: Quarterly GAAP Revenues of $92.1 Million; Reaffirms Full-Year 2026 Financial Outlook
- SEC Form 6-K filed by InMode Ltd.
- Steel Partners Holdings L.P. Issues Open Letter to All InMode Stakeholders and Sets October 30, 2026 Expiration for Its $16.75 Per Share All-Cash Offer
- InMode to Report Third Quarter 2026 Financial Results on November 11, 2026, Expects Third Quarter Revenue of $91.8 Million to $92.0 Million, Reiterates FY 2026 Revenue Guidance Between $365M-$375M
- SEC Form 6-K filed by InMode Ltd.
- InMode Advances RF Microneedling Comfort with the Launch of Morpheus8 Cool
- SEC Form 6-K filed by InMode Ltd.
- Chief Financial Officer Itzkovich Moshe was granted 14,000 units of Ordinary Shares, increasing direct ownership by 57% to 38,430 units (SEC Form 4)
- SEC Form 6-K filed by InMode Ltd.
- InMode Reports Second Quarter 2026 Financial Results: Quarterly GAAP Revenues of $95.6 Million, Consistent with the Second Quarter of 2025
Latest STXS
- Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
- Stereotaxis Announces Convertible Note Financing of Up To $24 Million
- First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
- Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
- Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
- Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
- Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
- University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
- SEC Form EFFECT filed by Stereotaxis Inc.